Ming Zhang

Prof. Ming Zhang


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2014 in Nature
Verified
Journal Article
Closed access
PDF file
HOHong Ouyang
Hong Ouyang
YXYuanchao Xue
Yuanchao Xue
YLYing Lin
Ying Lin
XZXiaohui Zhang
Xiaohui Zhang
LXLei Xi
Lei Xi
KZKang Zhang
Kang Zhang

1 April 2011 in Ophthalmology
Verified
Journal Article
Closed access
MZMing Zhang
Ming Zhang
JZJunjun Zhang
Junjun Zhang
MYMi Yan
Mi Yan
DLDelun Luo
Delun Luo
WZWenjin Zhu
Wenjin Zhu
KGKH902 Phase 1 Study Group
KH902 Phase 1 Study Group

24 November 2022 in Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
XWXue Wu
Xue Wu
MTMengying Tao
Mengying Tao
LZLing Zhu
Ling Zhu
TZTing Zhang
Ting Zhang
MZMing Zhang
Ming Zhang
Non-infectious uveitis (NIU) is a disorder with various etiologies and is characterized by eye inflammation, mainly affecting people of working age. An accurate diagnosis of NIU is crucial for appropriate therapy. The aim of therapy is to improve vision, relieve ocular inflammation, prevent relapse, and avoid treatment side effects. At present, corticosteroids are the mainstay of topical or systemic therapy. However, repeated injections are required for the treatment of chronic NIU. Recently, new drug delivery systems that may ensure intraocular delivery of therapeutic drug levels have been highlighted. Furthermore, with the development of immunosuppressants and biologics, specific therapies can be selected based on the needs of each patient. Immunosuppressants used in the treatment of NIU include calcineurin inhibitors and antimetabolites. However, systemic immunosuppressive therapy itself is associated with adverse effects due to the inhibition of immune function. In patients with refractory NIU or those who cannot tolerate corticosteroids and immunosuppressors, biologics have emerged as alternative treatments. Thus, to improve the prognosis of patients with NIU, NIU should be managed with different drugs according to the response to treatment and possible side effects.

12 June 2024 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
DWDongyue Wang
Dongyue Wang
TTTong Tang
Tong Tang
PLPeiheng Li
Peiheng Li
JZJing Zhao
Jing Zhao
BSBairong Shen
Bairong Shen
MZMing Zhang
Ming Zhang
Introduction: The global distribution and trends in the attributable burden of cataract risk have rarely been systematically explored. To guide the development of targeted and accurate cataract screening and treatment strategies, we analyzed the burden of cataract disease attributable to known risk factors.Method: This study utilized detailed cataract data from the Global Burden of Disease e 2019, and we analyzed disability-adjusted life years (DALYs) e each risk factor from 1990 to 2019. Additionally, we calculated estimated annual percentage changes (EAPCs) during the study period.Results: The results revealed that from 1990−2019, the global age-standardized DALYs of e attributable to particulate matter pollution, smoking, high fasting glucose plasma and high BMI showed steady downward trends (1990−2009: EAPC = −0.21 [−0.57 −0.14]); 2000−2009: EAPC = −0.95 [−1.01 −0.89]; 2010−2019: EAPC = −1.41 [−1.8 −1.02]). The age-standardized DALYs and mortality caused by each risk factor were highest in the low-middle sociodemographic index (SDI) region (EAPC = −1.77[(−2.19–−1.34)]). The overall disease burden of cataracts is lower in males than in females. When analyzing the EAPCs of cataract disease burden for each risk factor individually, we found that the age-standardized disability-adjusted life years caused by particulate matter pollution and smoking decreased (PMP1990-2009: EAPC = −0.53 [−0.9–−0.16]; 2000−2009: EAPC = −1.39 [−1.45--1.32]; 2010−2019: EAPC = −2.27 [−2.75–−1.79]; smoking 2000 to 2009: EAPC = −1.51 [−1.6–−1.43], 2009 to 2019: EAPC = −1.34 [−1.68–−1])), while high fasting plasma glucose and high body mass index increased annually (HFPG1990 to 1999: EAPC = 1.27 [0.89−1.65], 2000 to 2009: EAPC = 1.02 [0.82−1.22], 2010−2019: EAPC = 0.44 [0.19−0.68]; HBMI 1990 to 1999: EAPC = 1.65 [1.37−1.94], 2000 to 2009: EAPC = 1.56 [1.43−1.68], 2010−2019: EAPC = 1.47 [1.18−1.77]).Disscussion: The burden of cataracts caused by ambient particulate matter and smoking is increasing in low, low-middle SDI areas, and specific and effective measures are urgently needed. The results of this study suggest that reducing particulate matter pollution, quitting smoking, controlling blood glucose, and lowering BMI could play important roles in reducing the occurrence of cataracts, especially in older people.

25 August 2022 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
YZYifan Zhang
Yifan Zhang
LYLi Yang
Li Yang
YGYuzhu Gao
Yuzhu Gao
DZDan Zhang
Dan Zhang
YTYunhan Tao
Yunhan Tao
MZMing Zhang
Ming Zhang
Background: Parkinson’s disease (PD) is one of the most common neurodegenerative diseases in the aging population. Previous literature has reported thinning of the retinal nerve fiber layer, ganglion cell layer, inner plexiform layer, and photoreceptor layer in PD patients. However, very few studies have used swept-source optical coherence tomography (SS-OCT) to study the choroid and choriocapillaris vascular changes in PD and their correlations with altered contrast sensitivity. Methods: PD patients and controls were enrolled in the current study. We used a CSV-1000E instrument to assess contrast sensitivity and performed SS-OCT and SS-OCTA to measure outer retinal thickness, choroidal thickness, choriocapillaris flow density, choroidal vascular volume (CVV), and choroidal vascular index (CVI). Results: One hundred eyes of 52 PD patients and 200 eyes of 100 healthy controls were recruited in the present study. Our study found remarkably impaired contrast sensitivity in PD patients (all P < 0.05). Significant thinning of the outer retinal layer and the choroid was appreciated in the PD group compared with the healthy controls (all P < 0.05). Choriocapillaris flow density, CVI, and CVV were significantly decreased in PD patients compared with healthy controls (all P < 0.05). Contrast sensitivity was weakly associated with outer retina thickness in the 3 mm circular area, with 3 cycles per degree being the most relevant (r = 0.535, P < 0.001). Conclusion: Our study indicates that there is a significant decrease in contrast sensitivity, outer retina thickness, choriocapillaris flow density, CVI, and CVV in PD patients. This research has also identified a positive correlation between outer retina thickness and contrast sensitivity.

16 March 2024 in Phytomedicine
Verified
Journal Article
Open access
DWDongyue Wang
Dongyue Wang
YCYi Chen
Yi Chen
JLJiakun Li
Jiakun Li
EWErman Wu
Erman Wu
TTTong Tang
Tong Tang
MZMing Zhang
Ming Zhang
Age-related macular degeneration (AMD) is a chronic retinal disease that significantly influences the vision of the elderly. There is no effective treatment and prevention method. The pathogenic process behind AMD is complex, including oxidative stress, inflammation, and neovascularization. It has been demonstrated that several natural products can be used to manage AMD, but systematic summaries are lacking. PubMed, Web of Science, and ClinicalTrials.gov were searched using the keywords "Biological Products" AND "Macular Degeneration" for studies published within the last decade until May 2023 to summarize the latest findings on the prevention and treatment of age-related macular degeneration through the herbal medicines and functional foods. The eligible studies were screened, and the relevant information about the therapeutic action and mechanism of natural products used to treat AMD was extracted. Our findings demonstrate that natural substances, including retinol, phenols, and other natural products, prevent the development of new blood vessels and protect the retina from oxidative stress in cells and animal models. However, they have barely been examined in clinical studies. Natural products could be highly prospective candidate drugs used to treat AMD, and further preclinical and clinical research is required to validate it to control the disease.